CFDs are a leveraged product and can result in losses that exceed deposits. Please ensure you fully understand how CFDs work and what their risks are, and take care to manage your exposure. CFDs are a leveraged product and can result in losses that exceed deposits. Please ensure you fully understand how CFDs work and what their risks are, and take care to manage your exposure.

3 FTSE 100 stocks to watch in May

IG looks at some of the stand out blue-chip stocks to keep an eye on in May.

The FTSE 100 closed a touch lower on Tuesday, coming close to falling through 6000 levels, after UK Chancellor Rishi Sunak warned that the British economy could suffer a ‘severe recession’ as a result of the Covid-19 crisis.

‘Although we have put unprecedented mitigating actions in place, I certainly won’t be able to protect every job and every business,’ Sunak said during a Lords Economic Affairs meeting. ‘We’re already seeing that in the data, and no doubt there will be more hardship to come.’

The warning helped send the index 46 points lower on Tuesday as investors grow concerned about the long-term impact of the pandemic on demand for products and services. And with UK stocks experiencing high volatility amid the Covid-19 crisis, IG has honed in on some of the key blue-chip stocks to watch in May.


The drug maker is on the front line in the battle against Covid-19 and its share price has performed relatively well amid the crisis, with the stock falling 22% to a low of £13.74 per share in late March. Since then, however, the stock has rebounded, climbing 20% to close at £16.60 per share on Tuesday.

The company is expected to deliver a strong overall performance in 2020, with its first quarter (Q1) results in April giving investors something to smile about. Group sales were up 19% to £91 billion, reflecting increased demand..

GlaxoSmithKline has also maintained its 2020 full-year guidance, unlike numerous other FTSE 100 companies, with its adjusted earnings per share expected to slide by 1% - 4% at constant exchange rates.

‘This guidance reflected our expectations for growth in key new products, and the start of a two-year period in which we would continue to increase investment in these products and in our R&D pipeline, alongside implementation of our new programme which will prepare the group for separation,’ the company said.

Analysts are upbeat about GSK, with UBS, Goldman Sachs and DZ Bank all reiterating ‘buy’ ratings for the stock in May. Goldman Sachs is the most optimistic of the three, issuing a target price of £20.60, implying a potential upside of 24% for the stock.

Taylor Wimpey

The British homebuilder was performing well before the advent of the Covid-19 crisis and subsequent lockdown, with the stock climbing 20% to hit a high of 236p a share in mid-February. Since then, the stock has plummeted as much as 50% and remains 30% lower than its earlier high.

The UK government’s lockdown restrictions have hit the housing market hard, but investors will welcome Taylor Wimpey’s plans to commence a phased return to construction sites in May. The homebuilder also said that demand for new homes continues to rise, contending that house prices will remain comparable to where they were before the lockdown.

The easing of lockdown restrictions is certainly good news for the UK housing market and its homebuilders but while activity will soon resume, progress is likely to be slow, according to Hansen Lu, property economist at Capital Economics.

‘Our best guess is that at least a quarter of ongoing sales will end up cancelled,’ he said. ‘Many others will be delayed as buyers assess their job prospects, seek discounts, or wait to see if prices fall.’

Lu also is not as optimistic as Taylor Wimpey, with the economist expecting house sales to remain well below pre-crisis levels by the end of the year.


Despite delivering a lacklustre set of quarterly results due to the economic fallout from the Covid-19 pandemic, Lloyds remains the top pick among analysts covering the UK banking sector.

Citigroup analysts are particularly fond of the stock, upgrading its rating to ‘buy’ and issuing a target price of 42p per share, implying a potential upside of 44%.

The rationale behind its assessment of Lloyds comes down to the bank’s relatively healthy balance sheet, well-discounted asset quality risks and its likelihood of emerging from the Covid-19 crisis in a far stronger position than its rivals.

Lloyds is certainly looking like the best of a bad bunch following UK banks latest earnings season, with Barclays reporting a 38% decline in pre-tax profits to £913 million, following its £2.1 billion charge to cover bad debts – which it believes will soar to as much as £4.5 billion by the end of 2020.

Then there was HSBC which told investors that it may have to set aside £8.8 billion to cover loan losses in 2020, with the Covid-19 pandemic having a major economic impact in its main markets across Asia and Europe.

Lloyds closed at 29p per share on Tuesday.

Ready to start trading shares? Open a live account or practise on a demo.

This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.

React to global volatility

Market volatility continues as coronavirus dominates the global agenda. Trade with us to take advantage of:

  • Tight spreads – from just 1 point on major indices, and 2.8 on US crude
  • Guaranteed stops – they’re free to use, and you’ll only pay a small fee if they’re triggered
  • Round-the-clock assistance – our highly-skilled team are on hand to support you

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Friday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.